2 weeks Ago By ABMN Staff
Dai ichi Life Insurance Company Ltd trimmed its holdings in shares of DexCom, Inc. ( NASDAQ:DXCM – Free Report ) by 7.2% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission.
The fund owned 24,305 shares of the medical device company’s stock after selling 1,875 shares during the quarter. Dai ichi Life Insurance Company Ltd’s holdings in DexCom were worth $2,756,000 at the end of the most recent quarter. A number of other institutional investors have also recently bought and sold shares of the business.
Team Hewins LLC lifted its holdings in DexCom by 3.4% during the first quarter. Team Hewins LLC now owns 2,555 shares of the medical device company’s stock valued at $354,000 after purchasing an additional 83 shares during the last quarter.
Bleakley Financial Group LLC lifted its position in shares of DexCom by 1.3% during the first quarter. Bleakley Financial Group LLC now owns 6,856 shares of the medical device company’s stock worth $951,000 after acquiring an additional 87 shares in the last quarter.
Capital Insight Partners LLC boosted its holdings in shares of DexCom by 2.5% in the second quarter. Capital Insight Partners LLC now owns 3,690 shares of the medical device company’s stock worth $418,000 after acquiring an additional 90 shares during the period.
Gulf International Bank UK Ltd raised its stake in shares of DexCom by 0.3% during the 1st quarter. Gulf International Bank UK Ltd now owns 32,075 shares of the medical device company’s stock valued at $4,448,000 after purchasing an additional 93 shares during the period.
Finally, EverSource Wealth Advisors LLC lifted its holdings in DexCom by 10.1% during the 4th quarter. EverSource Wealth Advisors LLC now owns 1,071 shares of the medical device company’s stock worth $133,000 after purchasing an additional 98 shares in the last quarter.
Institutional investors own 97.75% of the company’s stock. Wall Street Analyst Weigh In Several brokerages have recently weighed in on DXCM.
Wells Fargo & Company decreased their price target on DexCom from $145.00 to $80.00 and set an “overweight” rating on the stock in a research report on Friday, July 26th.
Barclays lowered their price objective on DexCom from $138.00 to $113.00 and set an “equal weight” rating on the stock in a research report on Monday, July 29th.
Oppenheimer cut their price objective on DexCom from $150.00 to $115.00 and set an “outperform” rating for the company in a report on Friday, July 26th.
Royal Bank of Canada decreased their price target on shares of DexCom from $165.00 to $145.00 and set an “outperform” rating on the stock in a report on Friday, July 26th.
Finally, BTIG Research lowered their price target on DexCom from $156.00 to $120.00 and set a “buy” rating on the stock in a research report on Friday, July 26th.
Seven equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $112.
25. DexCom Trading Up 1.0 % NASDAQ:DXCM opened at $69.
51 on Monday. DexCom, Inc. has a 12 month low of $62.
34 and a 12 month high of $142.00. The company has a current ratio of 2.
82, a quick ratio of 2.48 and a debt-to-equity ratio of 1.00.
The company has a 50-day moving average price of $82.36 and a 200-day moving average price of $111.23.
The stock has a market cap of $27.64 billion, a price-to-earnings ratio of 44.85, a P/E/G ratio of 2.
12 and a beta of 1.18. DexCom ( NASDAQ:DXCM – Get Free Report ) last posted its earnings results on Thursday, July 25th.
The medical device company reported $0.43 earnings per share for the quarter, topping analysts’ consensus estimates of $0.39 by $0.
04. The firm had revenue of $1 billion for the quarter, compared to the consensus estimate of $1.04 billion.
DexCom had a return on equity of 31.41% and a net margin of 16.95%.
The business’s revenue for the quarter was up 15.3% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.
34 EPS. Equities analysts predict that DexCom, Inc. will post 1.
69 EPS for the current year. Insiders Place Their Bets In related news, EVP Michael Jon Brown sold 652 shares of the stock in a transaction dated Wednesday, July 31st. The shares were sold at an average price of $69.
55, for a total value of $45,346.60. Following the completion of the transaction, the executive vice president now directly owns 66,249 shares in the company, valued at approximately $4,607,617.
95. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink . In related news, EVP Michael Jon Brown sold 652 shares of the firm’s stock in a transaction that occurred on Wednesday, July 31st.
The stock was sold at an average price of $69.55, for a total transaction of $45,346.60.
Following the completion of the transaction, the executive vice president now owns 66,249 shares of the company’s stock, valued at approximately $4,607,617.95. The transaction was disclosed in a filing with the SEC, which can be accessed through this link .
Also, COO Jacob Steven Leach sold 746 shares of DexCom stock in a transaction on Monday, September 9th. The shares were sold at an average price of $69.15, for a total value of $51,585.
90. Following the transaction, the chief operating officer now owns 264,915 shares of the company’s stock, valued at approximately $18,318,872.25.
The disclosure for this sale can be found here . Over the last 90 days, insiders sold 2,483 shares of company stock worth $201,708. 0.
30% of the stock is owned by corporate insiders. About DexCom ( Free Report ) DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers.
Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. Read More Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter .
.
